Angioslide develops the PROTEUS Embolic Capture Angioplasty solution, a combined PTA balloon and embolic capture-and-removal device. PROTEUS has received FDA clearance and European CE Mark approval for lower limb use. The company intends to use new capital to expand in the USA, improve its product offering and validate the technology in additional vascular beds. Angioslide is privately held, was founded in 2005, and is led by CEO Lihu Avitov. It maintains regional offices in Europe and the US. The company raised $6.3M in a Series C to support these plans.

Total raised

$6M

Funding rounds

1

Latest round

Series C

Latest activity

Jan 2013